These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
393 related articles for article (PubMed ID: 32749892)
21. Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease. Kazi DS; Moran AE; Coxson PG; Penko J; Ollendorf DA; Pearson SD; Tice JA; Guzman D; Bibbins-Domingo K JAMA; 2016 Aug; 316(7):743-53. PubMed ID: 27533159 [TBL] [Abstract][Full Text] [Related]
22. An update on inclisiran for the treatment of elevated LDL cholesterol. Barkas F; Ray K Expert Opin Pharmacother; 2024 Mar; 25(4):349-358. PubMed ID: 38549399 [TBL] [Abstract][Full Text] [Related]
23. The clinical effects of inclisiran, a first-in-class LDL-C lowering siRNA therapy, on the LDL-C levels in Chinese patients with hypercholesterolemia. Luo Z; Huang Z; Sun F; Guo F; Wang Y; Kao S; Yang G; Huang J; Li J; Zhao S; He Y J Clin Lipidol; 2023; 17(3):392-400. PubMed ID: 37164838 [TBL] [Abstract][Full Text] [Related]
24. AMG 145, a monoclonal antibody against PCSK9, facilitates achievement of national cholesterol education program-adult treatment panel III low-density lipoprotein cholesterol goals among high-risk patients: an analysis from the LAPLACE-TIMI 57 trial (LDL-C assessment with PCSK9 monoclonal antibody inhibition combined with statin thErapy-thrombolysis in myocardial infarction 57). Desai NR; Giugliano RP; Zhou J; Kohli P; Somaratne R; Hoffman E; Liu T; Scott R; Wasserman SM; Sabatine MS J Am Coll Cardiol; 2014 Feb; 63(5):430-3. PubMed ID: 24161333 [TBL] [Abstract][Full Text] [Related]
25. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. A new drug class for the treatment of hypercholesterolemia. Ortega MartĂnez de Victoria E Endocrinol Diabetes Nutr; 2017; 64(7):341-344. PubMed ID: 28745604 [No Abstract] [Full Text] [Related]
26. Evaluating bococizumab, a monoclonal antibody to PCSK9, on lipid levels and clinical events in broad patient groups with and without prior cardiovascular events: Rationale and design of the Studies of PCSK9 Inhibition and the Reduction of vascular Events (SPIRE) Lipid Lowering and SPIRE Cardiovascular Outcomes Trials. Ridker PM; Amarenco P; Brunell R; Glynn RJ; Jukema JW; Kastelein JJ; Koenig W; Nissen S; Revkin J; Santos RD; Schwartz PF; Yunis C; Tardif JC; Am Heart J; 2016 Aug; 178():135-44. PubMed ID: 27502861 [TBL] [Abstract][Full Text] [Related]
27. Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial. Ray KK; Troquay RPT; Visseren FLJ; Leiter LA; Scott Wright R; Vikarunnessa S; Talloczy Z; Zang X; Maheux P; Lesogor A; Landmesser U Lancet Diabetes Endocrinol; 2023 Feb; 11(2):109-119. PubMed ID: 36620965 [TBL] [Abstract][Full Text] [Related]
36. Design and rationale of the GAUSS-2 study trial: a double-blind, ezetimibe-controlled phase 3 study of the efficacy and tolerability of evolocumab (AMG 145) in subjects with hypercholesterolemia who are intolerant of statin therapy. Cho L; Rocco M; Colquhoun D; Sullivan D; Rosenson RS; Dent R; Xue A; Scott R; Wasserman SM; Stroes E Clin Cardiol; 2014 Mar; 37(3):131-9. PubMed ID: 24477778 [TBL] [Abstract][Full Text] [Related]
37. Inclisiran: A First-in-Class siRNA Therapy for Lowering Low-Density Lipoprotein Cholesterol. Samuel E; Watford M; Egolum UO; Ombengi DN; Ling H; Cates DW Ann Pharmacother; 2023 Mar; 57(3):317-324. PubMed ID: 35775133 [TBL] [Abstract][Full Text] [Related]
38. The N-Acetylgalactosamine-conjugated small interfering RNA inclisiran can be coadministered safely with atorvastatin in cynomolgus monkeys resulting in additive low-density lipoprotein cholesterol reductions. Lehoux D; Kallend D; Wijngaard PLJ; Brown AP; Zerler B Pharmacol Res Perspect; 2023 Apr; 11(2):e01080. PubMed ID: 37021909 [TBL] [Abstract][Full Text] [Related]
39. Harnessing RNA Interference for Cholesterol Lowering: The Bench-to-Bedside Story of Inclisiran. Wilkinson MJ; Bajaj A; Brousseau ME; Taub PR J Am Heart Assoc; 2024 Mar; 13(6):e032031. PubMed ID: 38456415 [TBL] [Abstract][Full Text] [Related]
40. Non-statin Treatments for Managing LDL Cholesterol and Their Outcomes. Turner T; Stein EA Clin Ther; 2015 Dec; 37(12):2751-69. PubMed ID: 26548322 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]